Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial

The Lancet Haematology - Tập 5 - Trang e73-e81 - 2018
Claire N Harrison1, Alessandro M Vannucchi2, Uwe Platzbecker3, Francisco Cervantes4, Vikas Gupta5, David Lavie6, Francesco Passamonti7, Elliott F Winton8, Hua Dong9, Jun Kawashima9, Julia D Maltzman9, Jean-Jacques Kiladjian10, Srdan Verstovsek11
1Guy's and St Thomas' National Health Service Foundation Trust, London, UK
2Azienda Ospedaliera Careggi Dipartimento di Medicina Sperimentale e Clinica, University of Florence, Florence, Italy
3Medizinische Fakultät Carl Gustav Carus, Technische Universität, Dresden, Germany
4Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
5Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
6Hadassah Hebrew University Medical Center, Jerusalem, Israel
7University of Insubria, ASST Settelaghi, Ospedale di Circolo, Varese, Italy
8Emory University School of Medicine, Atlanta, GA, USA;
9Gilead Sciences, Inc., Foster City, CA, USA
10Saint-Louis Hospital (APHP) and Paris Diderot University, Paris, France
11University of Texas/MD Anderson Cancer Center, Houston, TX USA

Tài liệu tham khảo

Thông tin
Thông tin xuất bản

The Lancet Haematology

Tập 5

e73-e81

Thông tin tác giả